Pancreatic cancer study aims to uncover hidden barriers to clinical trial access
NCT ID NCT07591480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study interviews 20 pancreatic cancer patients to learn why certain groups—like racial minorities, low-income individuals, or rural residents—are less likely to join clinical trials. Researchers hope to find ways to make trials more accessible and fair for everyone. The study does not test any treatment or drug.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal specific barriers that prevent certain groups from joining clinical trials, leading to better outreach and more inclusive research.
- What could go wrong
- This is a small, early-stage qualitative study with only 20 participants, so findings may not apply to all pancreatic cancer patients or other diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
UT MD Anderson
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study * Males and females; Age ≥18 * Documented diagnosis of pancreatic cancer * Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access) Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Patients who speak a primary language other than English or Spanish * Patients who are cognitively impaired * Pregnant women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo crack pancreatic Cancer's defenses?
- Can a blood test before pancreatic surgery predict a dangerous leak?
- New chemo cocktail targets pancreatic cancer at every stage
- Bacteria-Based immunotherapy targets pancreatic tumors in first human test
- Can a new radiation machine cut breath holds for cancer patients?
- Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors